Post hoc analysis of SLS I and II in SSc-ILD (72 of 142 SLS II participants analysed): a composite of FVC, fibrosis extent, dyspnoea and disability gave larger effect sizes than FVC alone and better predicted long-term survival (HR 0.76 vs 0.98; 0.59 vs 0.98).
Secondary analysisn = 72
Volkmann et al. A composite endpoint for systemic sclerosis-associated interstitial lung disease: association with mortality in two clinical trial cohorts